Oxeladin API Manufacturers & Suppliers

Oxeladin (CAS Number 468-61-1) is an organic compound classified within the phenylpropane chemical class, characterized by the presence of a phenylpropane moiety. It has historically been utilized as an antitussive agent, acting on the central nervous system to suppress cough. Despite its previous medical use in cough and cold preparations and respiratory system treatments, oxeladin's clinical indication is not specifically defined in available data.

Pharmacodynamic and detailed mechanism of action information for oxeladin is not available in the literature. As an antitussive, it was presumably intended to modulate the cough reflex centrally, although precise receptor targets or pathways have not been documented.

The compound was withdrawn from the Canadian, United States, and United Kingdom markets in 1976 due to its association with carcinogenicity. Toxicological studies identified risks that outweighed therapeutic benefits, leading to its market removal. Due to this history, oxeladin is no longer approved for clinical use and carries significant safety concerns.

Key absorption, distribution, metabolism, and excretion (ADME) parameters have not been published or are inaccessible. Given its withdrawal and lack of contemporary data, current pharmaceutical use is effectively obsolete.

Oxeladin was historically marketed under various formulations as a cough suppressant but no notable brands remain active in current pharmaceutical channels. Regulatory oversight prohibits its clinical use in countries with stringent safety standards.

For formulation scientists and API sourcing professionals, strict due diligence is essential when handling oxeladin. Its carcinogenic potential mandates comprehensive quality control and compliance with hazardous substance regulations. Sourcing of oxeladin APIs should consider its regulatory status, potential legal constraints, and the necessity of validated purity and impurity profiles to ensure worker safety and environmental containment.